{
    "organizations": [],
    "uuid": "4a9babcc0d3e5043f6bb6b7975b48817e7864411",
    "author": "",
    "url": "https://www.reuters.com/article/brief-zealand-pharma-announces-progress/brief-zealand-pharma-announces-progress-to-phase-3-with-dasiglucagon-for-the-treatment-of-congenital-hyperinsulinism-idUSASM000IB6",
    "ord_in_thread": 0,
    "title": "BRIEF-Zealand Pharma Announces Progress To Phase 3 With Dasiglucagon For The Treatment Of Congenital Hyperinsulinism",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 19 (Reuters) - Zealand Pharma A/S:\n* ZEALAND PHARMA ANNOUNCES PROGRESS TO PHASE 3 WITH DASIGLUCAGON FOR THE TREATMENT OF CONGENITAL HYPERINSULINISM IN FIRST HALF 2018\n* ZEALAND PHARMA - U.S. FDA APPROVED ZEALAND‘S INVESTIGATIONAL NEW DRUG APPLICATION FOR INITIATION OF TWO PHASE 3 CLINICAL TRIALS OF DASIGLUCAGON IN CHI​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-20T00:36:00.000+02:00",
    "crawled": "2018-01-20T00:54:43.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "zealand",
        "pharma",
        "zealand",
        "pharma",
        "announces",
        "progress",
        "phase",
        "dasiglucagon",
        "treatment",
        "congenital",
        "hyperinsulinism",
        "first",
        "half",
        "zealand",
        "pharma",
        "fda",
        "approved",
        "zealand",
        "investigational",
        "new",
        "drug",
        "application",
        "initiation",
        "two",
        "phase",
        "clinical",
        "trial",
        "dasiglucagon",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}